This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Centre Hospitalier Unviersitaire De Caen, Katholieke Universiteit Leuven, National Institute of Health and Medical Research. Active years: 2019.
Company Filing History:
1 out of 1 
1 out of 630 
1 out of 1,853 
Years Active: 2019
Title: Nick Geukens: Innovator in Thrombotic Disorder Treatments
Introduction
Nick Geukens is a notable inventor based in Leuven, Belgium. He has made significant contributions to the field of medical research, particularly in the treatment of thrombotic disorders. His innovative approach has led to the development of a unique bispecific inhibitor that targets specific proteins involved in blood clotting.
Latest Patents
Geukens holds a patent for a bispecific inhibitor aimed at treating thrombotic disorders, such as acute thrombotic events like stroke and thromboembolism. The patent, titled "Dual targeting of TAFI and PAI-1," describes a novel approach that utilizes monoclonal antibodies to target TAFI and PAI-1. This bispecific inhibitor demonstrates efficacy both in the presence and absence of plasminogen activators, including tissue-type plasminogen activator (tPA). He has 1 patent to his name.
Career Highlights
Throughout his career, Nick Geukens has worked with prestigious institutions, including Katholieke Universiteit Leuven and the National Institute of Health and Medical Research. His research has focused on advancing therapeutic options for patients suffering from thrombotic conditions.
Collaborations
Geukens has collaborated with esteemed colleagues in his field, including Paul Declerck and Simon De Meyer. Their combined expertise has contributed to the success of his research endeavors.
Conclusion
Nick Geukens is a prominent figure in the realm of medical innovation, particularly in the treatment of thrombotic disorders. His work continues to pave the way for advancements in therapeutic strategies, ultimately benefiting patients worldwide.